EBC-46

Global soft tissue sarcoma pipeline constitutes 125+ companies developing 130+ treatment therapies, with significant progress in clinical trials across various stages of development.

DelveInsight's latest report reveals a robust pipeline with over 80 companies developing 100+ drug candidates for head and neck cancer, highlighting significant research momentum in this therapeutic area.

Stanford researchers have discovered that EBC-46, a compound already known for cancer treatment, demonstrates remarkable effectiveness in targeting dormant HIV cells. The study revealed that EBC-46 analogs achieved a 90% success rate in reversing HIV latency, quadrupling the effectiveness of existing treatments and marking a significant step toward a potential HIV cure.

A shelter dog named Shandy in Cape Coral experienced complete remission from a mast cell tumor after treatment with Tigilanol Tiglate.